The stock of Citius Pharmaceuticals Inc (CTXR) has gone up by 11.76% for the week, with a 19.40% rise in the past month and a -55.75% drop in the past quarter. The volatility ratio for the week is 20.28%, and the volatility levels for the past 30 days are 14.39% for CTXR. The simple moving average for the past 20 days is 33.54% for CTXR’s stock, with a -68.28% simple moving average for the past 200 days.
Is It Worth Investing in Citius Pharmaceuticals Inc (NASDAQ: CTXR) Right Now?
The 36-month beta value for CTXR is at 1.32. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTXR is 7.23M, and currently, shorts hold a 7.25% of that float. The average trading volume for CTXR on January 08, 2025 was 262.40K shares.
CTXR) stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR)’s stock price has gone rise by 11.76 in comparison to its previous close of 3.91, however, the company has experienced a 11.76% increase in its stock price over the last five trading days. prnewswire.com reported 2025-01-07 that CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with D. Boral Capital repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to D. Boral Capital is $9 based on the research report published on December 30, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see CTXR reach a price target of $4. The rating they have provided for CTXR stocks is “Buy” according to the report published on November 30th, 2021.
CTXR Trading at -18.53% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.66% of loss for the given period.
Volatility was left at 14.39%, however, over the last 30 days, the volatility rate increased by 20.28%, as shares surge +24.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.48% lower at present.
During the last 5 trading sessions, CTXR rose by +11.76%, which changed the moving average for the period of 200-days by -76.70% in comparison to the 20-day moving average, which settled at $3.27. In addition, Citius Pharmaceuticals Inc saw 9.25% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CTXR
The total capital return value is set at -0.52. Equity return is now at value -48.65, with -35.54 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In conclusion, Citius Pharmaceuticals Inc (CTXR) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
